Publication | Closed Access

Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity

InflammationMolecular PharmacologyHypertensionDoxorubicin-induced CardiotoxicityCardiovascular DiseaseAngiotensin At1-receptor AntagonismAntihypertensive TherapyPhysiologyPharmacologyCardiovascular PharmacologyVascular BiologyPharmacotherapyCardiovascular ToxicityMedicineAngiotensin-converting Enzyme Inhibition